Hematologic Malignancies
Article
10 Important VA Studies You Might Have Missed at ASH
Lost amid the headlining news at the Association American Society of Hematology meeting last week were significant research findings from VA...
Conference Coverage
2018: A banner year for hematology drug approvals
SAN DIEGO – There have been 32 new hematology drug approvals and the year isn’t over yet.
Video
CLL resistance mechanism to venetoclax identified
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
News
FDA approves rituximab biosimilar for lymphoma
Truxima is the first biosimilar approved in the United States to treat non-Hodgkin lymphoma.
News
FDA expands approval of brentuximab vedotin to PTCL
This is the first FDA approval of a treatment for newly-diagnosed PTCL.
News
Bortezomib may unlock resistance in WM with mutations
The study tested how a bortezomib treatment combination would perform in patients with CXCR4 mutations.
News
Azacitidine-nivolumab combo 'encouraging' in AML
The response rate was higher among patients who had not received prior treatment with hypomethylating agents.
News
P-BCMA-101 gains FDA regenerative medicine designation
The autologous CAR T-cell therapy being developed for multiple myeloma received regenerative medicine advanced therapy designation from the FDA....
News
What’s the Impact of Osteoporosis in Multiple Myeloma?
The researchers examined the relationship between the Fracture Risk Assessment Tool and the risk of death in women.
Conference Coverage
Variant not linked to CLL in Southeast Europe
DUBROVNIK, CROATIA – The PTPN22 R620W polymorphism was not associated with CLL in patients from Southeast Europe.